Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2008 1
2009 3
2010 1
2011 3
2012 3
2013 3
2014 4
2015 2
2016 4
2017 3
2018 5
2019 4
2021 6
2022 9
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Favorable Non-Hodgkin Lymphoma"
Page 1
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, Wang Y, Xu H, Dickinson M. Jacobson CA, et al. Transplant Cell Ther. 2024 Jan;30(1):77.e1-77.e15. doi: 10.1016/j.jtct.2023.10.017. Epub 2023 Oct 27. Transplant Cell Ther. 2024. PMID: 37890589 Free article.
Chimeric antigen receptor T cell (CAR-T) therapies, including axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), are innovative treatments for patients with relapsed or refractory (r/r) large B cell lymphoma (LBCL). Following initial regulatory approvals, r …
Chimeric antigen receptor T cell (CAR-T) therapies, including axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), are innovat …
Alcohol drinking and non-Hodgkin lymphoma risk: a systematic review and a meta-analysis.
Tramacere I, Pelucchi C, Bonifazi M, Bagnardi V, Rota M, Bellocco R, Scotti L, Islami F, Corrao G, Boffetta P, La Vecchia C, Negri E. Tramacere I, et al. Ann Oncol. 2012 Nov;23(11):2791-2798. doi: 10.1093/annonc/mds013. Epub 2012 Feb 22. Ann Oncol. 2012. PMID: 22357444 Free article. Review.
BACKGROUND: Whether an association between alcohol drinking and non-Hodgkin lymphoma (NHL) risk exists is an open question. In order to provide quantification of the issue, we carried out a meta-analysis of published data. ...RESULTS: The overall relative ris …
BACKGROUND: Whether an association between alcohol drinking and non-Hodgkin lymphoma (NHL) risk exists is an open quest …
Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and meta-analysis.
Sharda E, Patel RS, Juárez-Salcedo LM, Dalia S, Hanna CH, Gruhonjic H, Ponnaganti BS, Mhaskar R. Sharda E, et al. Leuk Res. 2021 Sep;108:106615. doi: 10.1016/j.leukres.2021.106615. Epub 2021 May 11. Leuk Res. 2021. PMID: 34052662 Review.
Non-Hodgkin's lymphoma continues to be a highly prevalent entity in the general population. Currently, there are multiple treatment schemes based on chemotherapeutic agents with a great success rate. However, there is a non-negligible percentage of pat …
Non-Hodgkin's lymphoma continues to be a highly prevalent entity in the general population. Currently, there are multip …
Primary extranodal vaginal non-hodgkin lymphoma: Diagnostic pitfalls and therapeutic challenges.
Petrillo M, Fara AM, Fedeli MA, Fozza C, Cossu A, Gulotta A, Dessole F, Piana A, Capobianco G, Tanda F, Dessole S. Petrillo M, et al. Histol Histopathol. 2019 Jul;34(7):723-730. doi: 10.14670/HH-18-085. Epub 2019 Jan 18. Histol Histopathol. 2019. PMID: 30656635
INTRODUCTION: Primary extranodal non-hodgkin vaginal lymphoma (PeNHVL) represents a rare entity, with few data published until now. ...PeNHVL is characterized by a very high sensitivity to chemotherapy and very favourable prognosis; therefore, radical …
INTRODUCTION: Primary extranodal non-hodgkin vaginal lymphoma (PeNHVL) represents a rare entity, with few data publishe …
Clinical characteristics and outcomes of IgG4-positive marginal zone lymphoma: Systematic scoping review.
Nishimura Y, Wien EA, Nishimura MF, Nishikori A, Sato Y, Otsuka F. Nishimura Y, et al. Pathol Int. 2022 Jul;72(7):361-370. doi: 10.1111/pin.13251. Epub 2022 Jun 9. Pathol Int. 2022. PMID: 35678201
Immunoglobulin G4 (IgG4)-positive marginal zone lymphoma (MZL) is rare and undefined. It is unclear whether IgG4-positive MZLs have as favorable an outcome as MZLs in general. ...While there seems to be IgG4-RD-related and de novo IgG4-positive MZLs, future research …
Immunoglobulin G4 (IgG4)-positive marginal zone lymphoma (MZL) is rare and undefined. It is unclear whether IgG4-positive MZLs have a …
Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis.
Roufarshbaf M, Javeri M, Akbari V, Matin PH, Farrokhi P, Sadeghi E, Heidari Z, Moghaddas A. Roufarshbaf M, et al. Daru. 2022 Dec;30(2):367-378. doi: 10.1007/s40199-022-00444-w. Epub 2022 Sep 3. Daru. 2022. PMID: 36057010 Free PMC article. Review.
OBJECTIVES: Since the US Food and Drug Administration (FDA) approved ibrutinib to treat patients with refractory/relapsed mantle cell lymphoma (R/R MCL), it is used in clinical trials, whether as a single agent or in combination with other chemotherapy agents. ...In our re …
OBJECTIVES: Since the US Food and Drug Administration (FDA) approved ibrutinib to treat patients with refractory/relapsed mantle cell lym …
Reappraisal of primary hepatic lymphoma: Is surgical resection underestimated?
Cesaretti M, Loustau M, Robba C, Senescende L, Zarzavadjian Le Bian A. Cesaretti M, et al. Crit Rev Oncol Hematol. 2018 Mar;123:1-6. doi: 10.1016/j.critrevonc.2018.01.004. Epub 2018 Jan 30. Crit Rev Oncol Hematol. 2018. PMID: 29482772 Review.
Primary hepatic lymphoma (PHL) is defined as a lympho-proliferative disorder limited to the liver without any involvement of the spleen, lymph nodes, bone marrow or blood. Diffuse large B-cell lymphoma (DLBCL) is the most common histological type counting more than …
Primary hepatic lymphoma (PHL) is defined as a lympho-proliferative disorder limited to the liver without any involvement of the sple …
Woringer-Kolopp disease (localized pagetoid reticulosis): a systematic review.
Osto M, Afify O, Musa A, Ahmed U, Rehman R, Mehregan D. Osto M, et al. Int J Dermatol. 2023 Mar;62(3):312-321. doi: 10.1111/ijd.16224. Epub 2022 Apr 29. Int J Dermatol. 2023. PMID: 35485962 Review.
Studies were included if they contained primary data related to WKD. Non-pertinent studies, non-English studies, non-human studies, review articles, or studies with insufficient case information were excluded. ...In total, 92 (78.6%) cases had complete remiss …
Studies were included if they contained primary data related to WKD. Non-pertinent studies, non-English studies, non-hu …
A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma.
Gustavsson A, Osterman B, Cavallin-Ståhl E. Gustavsson A, et al. Acta Oncol. 2003;42(5-6):605-19. doi: 10.1080/02841860310014435. Acta Oncol. 2003. PMID: 14596518 Review.
The procedures for evaluation of the scientific literature are described separately (Acta Oncol 2003; 42: 357-365). This synthesis of the literature on radiation therapy for non-Hodgkin's lymphoma (NHL) is based on data from seven randomized trials. ...Data i …
The procedures for evaluation of the scientific literature are described separately (Acta Oncol 2003; 42: 357-365). This synthesis of the li …
Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C, Hind D, Brewer N, Abbott V. Knight C, et al. Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82. doi: 10.3310/hta8370. Health Technol Assess. 2004. PMID: 15361313 Free article. Review.
OBJECTIVES: To determine the clinical and cost-effectiveness of adding rituximab to the CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy regime for adult patients with diffuse large B-cell lymphoma (DLBCL). DATA SOURCES: Electronic bibliographic …
OBJECTIVES: To determine the clinical and cost-effectiveness of adding rituximab to the CHOP (cyclophosphamide, doxorubicin, vincristine, pr …
47 results